Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autoimmune Disorders

Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis

Abstract

We retrospectively evaluated the efficacy of autologous hematopoietic stem cell transplantation (AHSCT) in 18 patients with rapidly progressive diffuse cutaneous systemic sclerosis (rp-dcSSc), and compared their disease outcomes with those of 36 demographically- and clinically-matched patients treated with conventional therapies. Cutaneous involvement, by performing modified Rodnan skin score (mRss), lung diffusion capacity, by measuring diffusing capacity of lung for carbon monoxide (DLCO), and disease activity, by applying the European Scleroderma Study Group (ESSG) scoring system, were the outcome variables measured at the baseline time and then every 12 months for the following 60 months in both the AHSCT-treated patients and the control group. In the AHSCT group, treatment-related mortality was 5.6%. In this group, both mRss and ESSG scores showed a significant reduction 1 year after AHSCT (P<0.002); and these results were maintained until the end of follow-up. Conversely, DLCO values remained stable during the whole period of follow-up. Survival rate of AHSCT group was much higher than that observed in the whole control group (P=0.0005). The probability that the ESSG score and mRss would remain at a high level, and DLCO could decrease, was significantly higher in the control group as a whole and in the subgroup of control patients treated with cyclophosphamide than in the AHSCT group. This study confirms that the AHSCT is effective in prolonging survival, as well as in inducing a rapid reduction of skin involvement and disease activity, and preserving lung function in patients with rp-dcSSc.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Gabrielli A, Avvedimento EV, Krieg T . Scleroderma. N Engl J Med 2009; 360: 1989–2003.

    Article  CAS  Google Scholar 

  2. Nagaraja V, Denton CP, Khanna D . Old medications and new targeted therapies in systemic sclerosis. Rheumatology 2015; 54: 1944–1953.

    Article  CAS  Google Scholar 

  3. Ferri C, Sebastiani M, Lo Monaco A, Iudici M, Giuggioli D, Furini F et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 2014; 13: 1026–1034.

    Article  Google Scholar 

  4. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620–628.

    Article  CAS  Google Scholar 

  5. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.

    Article  CAS  Google Scholar 

  6. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962–3970.

    Article  CAS  Google Scholar 

  7. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026–1034.

    Article  CAS  Google Scholar 

  8. Broad K, Pope JE . The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit 2010; 16: RA187–RA190.

    PubMed  Google Scholar 

  9. Nannini C, West CP, Erwin PJ, Matteson EL . Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10: R124.

    Article  Google Scholar 

  10. Young A, Khanna D . Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol 2015; 27: 241–248.

    Article  CAS  Google Scholar 

  11. Naraghi K, van Laar JM . Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep 2013; 15: 326–331.

    Article  Google Scholar 

  12. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498–506.

    Article  CAS  Google Scholar 

  13. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490–2498.

    Article  CAS  Google Scholar 

  14. ClinicalTrials.gov:Scleroderma: Cyclophosphamide or Transplantation (SCOT). Available at http://www.clinicaltrials.gov/ct2/show/ NCT00114530?term=SCOT&rank=3. Accessed July 2015.

  15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–590.

    Article  Google Scholar 

  16. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737–2747.

    Article  Google Scholar 

  17. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892–1896.

    CAS  PubMed  Google Scholar 

  18. Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003; 62: 901–903.

    Article  CAS  Google Scholar 

  19. Medsger TA . Natural history of systemic sclerosis and the assessment of severity, functional state, and phychologic well-being. Rheum Dis Clin North Am 2003; 29: 255–273.

    Article  Google Scholar 

  20. Oliveira MC, Labopin M, Henes J, Moore J, Papa ND, Cras et al. Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant 2016; 51: 501–505.

    Article  CAS  Google Scholar 

  21. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr . Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70: 104–109.

    Article  Google Scholar 

  22. Maurer B, Graf N, Michel BA, Müller-Ladner U, Czirják L, Denton CP et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015; 74: 1124–1131.

    Article  CAS  Google Scholar 

  23. Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116–1124.

    Article  Google Scholar 

  24. van Laar JM, Naraghi K, Tyndall A . Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology 2015; 54: 2126–2133.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N Del Papa.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Del Papa, N., Onida, F., Zaccara, E. et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 52, 53–58 (2017). https://doi.org/10.1038/bmt.2016.211

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.211

This article is cited by

Search

Quick links